首页> 外文OA文献 >Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

【2h】

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

机译：在晚期HER2阴性乳腺癌患者中，口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M. E. Cazzaniga; null null; L. Cortesi; A. Ferzi; L. Scaltriti; F. Cicchiello; M. Ciccarese; S. Della Torre; F. Villa; M. Giordano; C. Verusio; M. Nicolini; A. R. Gambaro; L. Zanlorenzi; E. Biraghi; L. Legramandi; E. Rulli;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study [J] . Cazzaniga M. E., Cortesi L., Ferzi A., Breast cancer research and treatment. . 2016,第3期

机译：在晚期HER2阴性乳腺癌患者中，口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果
2. Metronomic combination of vinorelbine (VNR) and capecitabine (CAPE) in HER2-negative advanced breast cancer (ABC) patients (pts): Preliminary results of efficacy and safety of the VICTOR-2 study [J] . Cazzaniga M. E., Porcu L., Cortesi L., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：长春瑞滨（VNR）和卡培他滨（CAPE）在HER2阴性晚期乳腺癌（ABC）患者中的组学组合：VICTOR-2研究的有效性和安全性的初步结果
3. METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2-ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY [J] . Cazzaniga Marina Elena, Torri Valter, Cortesi Laura, The Breast : . 2015,第Suppla3期

机译：HER2晚期乳腺癌（ABC）患者（PTS）中长春瑞滨（VRL）和卡培他滨（CAPE）的均等化学疗法（CHT）并不会损害全球QOL。 VICTOR-2研究的第一结果
4. Use of Laser Photomodulation in the Evolution of Oral Mucositis Associated to Cyclophosphamide, Methotrexate, 5-Fluouracil - CMF in 5 Fluouracil + Adriamycin + Cyclophosphamide - FAC Chemotherapy Protocols in Patients with Breast Cancer [C] . Maria de Fatima Lima Ferreira, Fabiola Bastos de Carvalho, Susana C. P. S. de Oliveira, Mechanisms for low-light therapy VIII . 2013

机译：激光光调节在5种氟尿嘧啶+阿霉素+环磷酰胺-FAC化疗方案中与环磷酰胺，甲氨蝶呤，5-氟尿嘧啶-CMF相关的口腔黏膜演变中的应用
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study [O] . M. E. Cazzaniga, L. Cortesi, A. Ferzi, -1

机译：在晚期HER2阴性乳腺癌患者中口服长春瑞滨（mVNR）和卡培他滨（mCAPE）进行节律化疗：这是优化疾病控制的一种方法吗？ VICTOR-2研究的最终结果
7. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro - AGO-B-046 [O] . S Krajnak, T Decker, L Schollenberger, 2021

机译：II期研究对每日口服血上的衡量治疗作为一线化疗，患者先进/转移性HR + / HER2-乳腺癌对内分泌治疗的抗性：VINOFORGRO-AGO-B-046

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

著录项

引文网络

相似文献

相关主题

期刊订阅